Figure 2.
![Sustained FIX activity over 5-year follow-up after etranacogene dezaparvovec administration. FIX activity was sustained across the 5 years of follow-up for all study participants, increasing to a mean (SD; range) 30.57% (6.97; 23.9-37.8) at week 6 that remained stable and in the nonhemophilia range from year 1 (40.77% [9.45; 31.3-50.2]) to year 5 (45.7% [6.18; 39.0-51.2]). ∗HemosIL SynthASil reagent. aPTT, activated partial thromboplastin time.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/14/10.1182_bloodadvances.2024015291/1/blooda_adv-2024-015291-gr2.jpeg?Expires=1755635672&Signature=CERypEyQdr3hUEUKjJyugRyruyPgVxITNTW1ihAGbKIxq5u4LyxNdon0hxhuzgFw~YdqRtqQ11bn~Ih7ZOo8UTVcFDf44AM4k2wCv71c7zj4Q5iwsQnOPgBCJIp-9TjacHm0EHdsmYG~LH9pmnXYACf5OaRYDR3P3aGJIpKetHJYWgKyXNlJNhQV1S3DSTjHNoIRGNxEJyZkdBRgGLaLbPWfPSpVRb7joKMQgI5uERe8hug2j9~ZfHt3ARu4eXj2syBmaCRXBeBikgqgfjQkxVg5BZiPw7QOCh1j3vmz8hLeIze03uCZaQJkrryznSZmdsHaRF0oFHFyoh3oVkfFwQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Sustained FIX activity over 5-year follow-up after etranacogene dezaparvovec administration. FIX activity was sustained across the 5 years of follow-up for all study participants, increasing to a mean (SD; range) 30.57% (6.97; 23.9-37.8) at week 6 that remained stable and in the nonhemophilia range from year 1 (40.77% [9.45; 31.3-50.2]) to year 5 (45.7% [6.18; 39.0-51.2]). ∗HemosIL SynthASil reagent. aPTT, activated partial thromboplastin time.
